| 李晓娟,周 亮,金丽娟,朱 瑞,田 娟.血必净联合利奈唑胺注射液对老年重症肺炎患者血清肺表面活性蛋白、基质金属蛋白酶及其组织抑制剂水平的影响[J].,2018,(24):4773-4777 |
| 血必净联合利奈唑胺注射液对老年重症肺炎患者血清肺表面活性蛋白、基质金属蛋白酶及其组织抑制剂水平的影响 |
| Effects of Xuebijing Combined with Linazolamide Injection on the Serum Lung Surface Active Proteins, Matrix Metalloproteinases and Tissue Inhibitors Levels in the Elderly Patients with Severe Pneumonia |
| 投稿时间：2018-08-07 修订日期：2018-08-31 |
| DOI：10.13241/j.cnki.pmb.2018.24.039 |
| 中文关键词: 老年重症肺炎 血必净 利奈唑胺注射液 肺表面活性蛋白 基质金属蛋白酶 基质金属蛋白酶组织抑制剂 |
| 英文关键词: Elderly Severe Pneumonia Xuebijing Linazolamide Injection Lung Surface Active Protein Matrix Metalloproteinase Matrix Metalloproteinase Tissue Inhibitor |
| 基金项目:宁夏回族自治区自然科学基金项目(NZ11189) |
|
| 摘要点击次数: 279 |
| 全文下载次数: 101 |
| 中文摘要: |
| 摘要 目的：探讨血必净联合利奈唑胺注射液治疗老年重症肺炎患者的临床疗效及对患者血清肺表面活性蛋白(Pulmonary surfac- tant protein，SP)、基质金属蛋白酶(Matrix metalloproteinases，MMPs)及其组织抑制剂(Matrix metalloproteinases tissue inhibitor，TIMPs)水平的影响。方法：选择我院2015年6月~2017年12月收治的101例老年重症肺炎患者，按随机数字表法分为对照组(n=48)和研究组(n=53)。对照组采用利奈唑胺注射液治疗，研究组在对照组基础上采用血必净治疗。比较两组临床疗效，细菌清除情况，症状缓解时间，治疗前后血清SP、MMPs、TIMPs水平的变化，动脉血气，肺功能，不良反应的发生情况和28天内病死率。结果：治疗后，研究组有效率、细菌清除率均显著高于对照组(均P<0.05)，发热消失、血常规恢复、痰液颜色改变及胸部影像明显吸收时间均明显短于对照组(P<0.05)；两组血清SP-A、SP-B、SP-C、SP-D、MMP-2、MMP-9及TIMP-1及TIMP-2、血氧饱和度(blood oxy- gen saturation，SaO2)、动脉血二氧化碳分压(arterial blood，PaCO2)、动脉血二氧化碳分压(arterial blood CO2 partial pressure of CO2 partial pressure，PaCO2)、峰流速(peak velocity of flow，PEF)水平均较治疗前显著下降，而血氧饱和度(blood oxygen saturation，SaO2)、氧分压(oxygen partial pressure，PaO2)、最大呼气中段流量(maximum tidal midexpiratory flow，MMF)、用力肺活量(forced vital capacity，FVC)均较治疗前明显上升，且研究组以上指标变化较对照组更明显(均P<0.05)。两组不良反应的发生情况比较差异无统计学意义(P>0.05)，而研究组在28天内病死率显著低于对照组(P<0.05)。结论：血必净联合利奈唑胺注射液对老年重症肺炎患者的疗效优于单用利奈唑胺注射液治疗，可能与其显著降低患者血清SP、MMPs及TIMPs水平，改善肺功能，降低病死率有关。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical efficacy of xuebijing combined with linazolamide injection in the treatment of elderly patients with severe pneumonia and its effect on serum levels of pulmonary surface active protein (SP), matrix metalloproteinase (MMPs) and tissue inhibitor(TIMPs). Methods: 101 cases of elderly severe pneumonia who treated from June 2015 to December 2017 in our hos -pital, according to the random number table method, those patients were divided into the control group (n=48) and the research group (n=53). The control group was treated with linazolamide injection, and the research group was treated with xuebijing based on the control group. Then clinical efficacy, bacterial clearance, symptom relief time, changes of SP, MMPs and TIMPs levels before and after treat- ment, the occurrence of adverse reactions and mortality within 28 days in both group were compared. Results: After treatment, effective rate in research group was significant higher than that of the control group (P<0.05). disappearance of fever, restoration of blood routine, change of sputum color, and apparent absorption time of chest image in research group were significant lower than that in the control group(P<0.05). After treatment, serum levels of SP-A, SP-B, the SP-C, SP-D, MMP-2, MMP-9 and TIMP-1 and TIMP-2, blood oxygen saturation(SaO2), arterial blood(PaCO2), arterial blood CO2 partial pressure of CO2 partial pressure(PaCO2), peak velocity of flow (PEF) in both group was significant reduction than before the treatment, and blood oxygen saturation(SaO2), oxygen partial pressure(PaO2), maxi- mum tidal midexpiratory flow(MMF) and forced vital capacity(FVC) was significant increase than before the treatmen, the changes of the above indexes in the research group were more obvious than those in the control group, and the differences were statistically significant(all P<0.05). adverse reactions in both group was no significant difference(P>0.05). Fatality rate with 28 days in research group was lower than that of the control group (P<0.05). Conclusion: The curative effect of xuebijing combined with linezolid injection on elderly patients with severe pneumonia is better than that of linezolid injection alone, which may be related to significantly reducing the serum levels of SP, MMPs and TIMPs, improving lung function and reducing the mortality of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
